A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

被引:14
|
作者
Lombard, Louise [1 ]
Nutr, M. [1 ]
Ye, Wenyu [1 ]
Nichols, Russell [1 ]
Jackson, James [2 ]
Cotton, Sarah [2 ]
Joshi, Shivang [3 ,4 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Adelphi Real World, Adelphi Mill, Bollington, England
[3] DENT Neurol Inst, Amherst, NY USA
[4] Univ Buffalo, Sch Pharm, Buffalo, NY USA
来源
HEADACHE | 2020年 / 60卷 / 07期
关键词
migraine; responder; insufficient responder; real-world; acute treatment; UNITED-STATES; PREVALENCE; HEADACHE; PREVENTION; NONRESPONDERS; DISABILITY; TRIALS; ADULTS;
D O I
10.1111/head.13835
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective The objective of this study was to examine if patients with migraine who responded sufficiently to acute treatment were significantly different from those who did not in terms of patient characteristics, treatment patterns, and patient level of impairment, and to identify characteristics associated with insufficient response. Background Migraine is highly prevalent and impacts functional ability substantially. Current treatment approaches are not sufficiently meeting the needs of patients, and inadequate response to acute treatment is reported by at least 56% of patients with migraine in the United States. Methods Data were obtained from the 2014 Adelphi Migraine Disease-Specific Program, a cross-sectional survey. Using logistic regression, we assessed the association between patient factors and insufficient response. Responders were defined as patients with migraine who achieved pain freedom within 2 hours of acute treatment in >= 4 of 5 attacks, while insufficient responders achieved it in <= 3 of 5 attacks. Results Of 583 patients included, insufficient responders to acute treatment constituted 34.3% (200/583) of the study population. A statistically significantly larger proportion of insufficient responders vs responders had >= 4 migraine headache days/month (46.3% [88/190] vs 31% [114/368]), had ever been prescribed >= 3 unique preventive treatment regimens (11.7% [21/179] vs 6.3% [22/347]), and had chronic migraine, medication-overuse headaches, and comorbid depression (all P values <=.05). Patient level of impairment was statistically significantly greater among insufficient responders vs responders. Factors associated with insufficient response after adjusting for covariates included Migraine Disability Assessment total score (odds ratio [OR] = 1.04, 95% CI [1.02, 1.05]), time of administration of acute treatment (OR = 1.83, 95% CI [1.15, 2.92]), depression (OR = 1.98, 95% CI [1.21, 3.23]), sensitivity to light not listed as current most troublesome symptom (OR = 2.30, 95% CI [1.21, 4.37]), and change in the average headache days per month before being prescribed an acute treatment vs now (OR = 1.75, 95% CI [1.05, 2.90]). Conclusions Clinical characteristics, treatment patterns, and health-related quality of life measures are statistically significantly different between insufficient responders and responders to acute treatment in patients with migraine.
引用
收藏
页码:1325 / 1339
页数:15
相关论文
共 50 条
  • [31] Real-World Patient Characteristics, Testing and Treatment Patterns of ALK plus NSCLC
    Gubens, M.
    Wong, W.
    Wu, N.
    Chu, L.
    Schulze, K.
    Illei, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1894 - S1895
  • [32] Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders
    Rinzivillo, M.
    De Felice, I
    Magi, L.
    Prosperi, D.
    Lannicelli, E.
    Signore, A.
    Annibale, B.
    Panzuto, F.
    NEUROENDOCRINOLOGY, 2020, 110 : 216 - 216
  • [33] Patient characteristics and treatment patterns in patients with advanced or recurrent endometrial cancer in Europe: A real-world study
    Shen, Qin
    Hunger, Matthias
    Pahwa, Ankit
    Schade, Rene
    Boklage, Susan
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S178 - S178
  • [34] Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib
    Passamonti, Francesco
    Parikh, Rohan C.
    Korgaonkar, Siddhi
    Chevli, Manoj
    Slaff, Samantha
    Rombi, Julien
    Adeyemi, Basirat
    Davis, Keith L.
    Yucel, Aylin
    BLOOD, 2023, 142
  • [35] Acute Treatment of Migraine in Adolescents: Real-World Analysis of Remote Electrical Neuromodulation ( REN)
    Esparham, A.
    Stark-Inbar, A.
    Garas, S.
    Ironi, A.
    Gautreaux, J.
    Rao, R.
    HEADACHE, 2023, 63 : 116 - 117
  • [36] Acute Treatment of Migraine in Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)
    Esparham, Anna
    Stark-Inbar, Alit
    Jekel, Leia
    Tamir, Shira
    Rabany, Liron
    Ironi, Alon
    Gautreaux, Jessica
    Rao, Rashmi
    PEDIATRIC NEUROLOGY, 2023, 142 : 51 - 55
  • [37] Analysis of Treatment Change of Acute Prescription Migraine Medications Using Real-World Evidence
    Lipton, R. B.
    Silberstein, S. D.
    Baradaran, S.
    Shewale, A. R.
    Cotton, S.
    Jackson, J.
    Viswanathan, H. N.
    HEADACHE, 2019, 59 : 83 - 83
  • [38] Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients
    Kwon, Soonwook
    Gil, Young-Eun
    Lee, Mi Ji
    CEPHALALGIA, 2022, 42 (08) : 705 - 714
  • [39] Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis
    Gaul, Charly
    Seidel, Karolin
    Heuck, Alexander
    Silaidos, Carmina
    Mrosowsky, Thora
    Eberhardt, Alice
    Fritz, Bjorn
    Jacob, Christian
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 667 - 678
  • [40] REAL-WORLD TREATMENT PATTERNS AND PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA ACROSS EUROPE
    Fernandez, A.
    Zomas, A.
    Papakostas, E.
    Do, T.
    Russo, M.
    D'Ambrosio, R.
    Schneidewind, G.
    HAEMATOLOGICA, 2017, 102 : 517 - 518